STOCK TITAN
  1. Home
  2. Sec-filings
  3. CCCC
  4. [Form 4] C4 Therapeutics, Inc. Insider Trading Activity

C4 Therapeutics (NASDAQ: CCCC) awards CAO 56,980 RSUs and updates holdings

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

C4 Therapeutics Chief Accounting Officer Mark Mossler reported equity compensation and related share movements. He received a grant of 56,980 restricted stock units, each representing one future share of common stock upon vesting and settlement.

According to the grant terms, 28,490 RSUs vest in three equal annual installments starting on February 13, 2027, and 28,490 RSUs vest in full on February 13, 2029, subject to performance milestones. Separately, 9,420 shares of common stock were acquired upon vesting of previously disclosed RSU awards, while 3,268 shares were withheld by the company at a price of $1.89 per share to cover tax obligations, which the filing specifies is not a sale. After these transactions, Mossler directly holds 71,916 shares of common stock.

Positive

  • None.

Negative

  • None.
Insider Mossler Mark
Role Chief Accounting Officer
Type Security Shares Price Value
Exercise Common Stock 9,420 $0.00 --
Tax Withholding Common Stock 3,268 $1.89 $6K
Grant/Award Common Stock 56,980 $0.00 --
Holdings After Transaction: Common Stock — 75,184 shares (Direct)
Footnotes (1)
  1. Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 28,490 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 28,490 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones. Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on April 10, 2024 and February 18, 2025. Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Mossler Mark
(Last) (First) (Middle)
C/O C4 THERAPEUTICS, INC.
490 ARSENAL WAY #120
(Street)
WATERTOWN MA 02472
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
C4 Therapeutics, Inc. [ CCCC ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Accounting Officer
3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/13/2026 A 56,980(1) A $0 75,184 D
Common Stock 02/14/2026 M(2) V 9,420 A $0 75,184 D
Common Stock 02/14/2026 F(3) 3,268 D $1.89 71,916 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 28,490 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 28,490 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones.
2. Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on April 10, 2024 and February 18, 2025.
3. Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person.
Remarks:
/s/ Shagha Russell, Attorney-in-Fact 02/18/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did C4 Therapeutics (CCCC) executive Mark Mossler report in this Form 4?

Mark Mossler, Chief Accounting Officer of C4 Therapeutics, reported a new grant of 56,980 restricted stock units and share movements tied to RSU vesting and tax withholding. These transactions adjust his equity-based compensation and directly held common stock position.

How many RSUs did C4 Therapeutics grant to its Chief Accounting Officer?

C4 Therapeutics granted Chief Accounting Officer Mark Mossler 56,980 restricted stock units. Each RSU represents the contingent right to receive one share of common stock upon vesting and settlement, forming a significant component of his long-term, stock-based compensation package.

What is the vesting schedule for Mark Mossler’s 56,980 RSUs at C4 Therapeutics (CCCC)?

Of the 56,980 RSUs, 28,490 vest in three equal annual installments starting February 13, 2027. The remaining 28,490 vest in full on February 13, 2029, contingent on certain performance milestones described in the award terms.

Why were 3,268 C4 Therapeutics shares disposed of in Mossler’s Form 4?

The 3,268 C4 Therapeutics shares were withheld by the company at $1.89 per share to satisfy tax withholding obligations on RSU vesting. The filing clarifies this is a tax-withholding disposition and does not represent an open-market sale by Mark Mossler.

How many C4 Therapeutics (CCCC) shares does Mark Mossler own after these transactions?

After the reported RSU grant, vesting, and tax-withholding disposition, Mark Mossler directly holds 71,916 shares of C4 Therapeutics common stock. This figure reflects his updated ownership following the February 2026 equity compensation events.

What triggered the 9,420-share acquisition reported by C4 Therapeutics’ CAO?

The 9,420-share acquisition reflects common stock received upon vesting of previously disclosed RSU grants. These RSUs were originally reported in earlier Forms 4, and their settlement converted units into directly held C4 Therapeutics common shares.